Terms: = Sarcomas AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA AND Prognosis
4 results:
1. Comparative oncology reveals DNMT3B as a molecular vulnerability in undifferentiated pleomorphic sarcoma.
Fuller AM; DeVine A; Murazzi I; Mason NJ; Weber K; Eisinger-Mathason TSK
Cell Oncol (Dordr); 2022 Dec; 45(6):1277-1295. PubMed ID: 36181640
[TBL] [Abstract] [Full Text] [Related]
2. Systemic mastocytosis with myeloid sarcoma and B-CLL: molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature.
Decruyenaere P; Mazure D; Moors I; Van Dorpe J; Van der Linden M; Denys B; Hofmans M; Offner F
Acta Clin Belg; 2023 Feb; 78(1):58-66. PubMed ID: 35098906
[TBL] [Abstract] [Full Text] [Related]
3. Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations.
Yilmaz A; Mohamed N; Patterson KA; Tang Y; Shilo K; Villalona-Calero MA; Davis ME; Zhou X; Frankel W; Otterson GA; Beall HD; Zhao W
Int J Environ Res Public Health; 2014 Sep; 11(9):9491-502. PubMed ID: 25222473
[TBL] [Abstract] [Full Text] [Related]
4. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
[TBL] [Abstract] [Full Text] [Related]
